Medical Cannabis Resource Library


  1. Abrams DI and Guzman M. Cannabis in Cancer Care. Clinical Pharmacology & Therapeutics, Volume 97 Number 6, June 2015, doi:10.1002/cpt.108

  2. Abrams etal, Cannabis in painful HIV-associated sensory neuropathy, Neurology 2007;68:515-521

  3. Adelli GR, Bhagav P, Taskar P, et al. Development of a D9-tetrahydrocannabinol amino acid-dicarboxylate prodrug with improved ocular bioavailability. Invest Ophthalmol Vis Sci. 2017;58:2167–2179. DOI:10.1167/iovs.16-20757

  4. Aggarwal SK. Cannabinergic Pain Medicine: A Concise Clinical Primer and Survey of Randomized-controlled Trial Results. Clinical Journal of Pain. 2012.

  5. Aquino G. Medicinal Marijuana: A Legitimate Appetite Stimulant? Department of Biological Chemistry. UCLA, David Geffen School of Medicine, Nutrition Bytes, Volume 10, Issue 1,  2005

  6. Babson etal, Cannabis Cannabinoids and Sleep – A Review of the Literature, Curr Psychiatry Rep (2017) 19:23  DOI 10.1007/s11920-017-0775-9

  7. Blake, et al, Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis,  Rheumatology 2006;45:50–52.    doi:10.1093/rheumatology/kei183

  8. Blass, Treating depression with cannabinoids, Cannabinoids 2008;3(2):8-10

  9. Bolognini etal, Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation, British Journal of Pharmacology (2013) 168 1456–1470

  10. Carter GT, Abood ME, Aggarwal SK, Weiss MD. 2010. Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials. American Journal of Hospice & Palliative Medicine 27: 347‐356.  doi: 10.1177/1049909110369531

  11. Centonze D, et al. The Endocannabinoid System Is Dysregulated in Multiple Sclerosis and in Experimental Autoimmune Encephalomyelitis. Oxford University Press. Brain. 2007;130(10):2543-2553. 2007

  12. Corey-Bloom J, et al. Smoked Cannabis for Spasticity in Multiple Sclerosis: A Randomized Placebo Controlled Trial. CMAJ 2012. DOI:10.1503 /cmaj.110837

  13. Costantino CM, Gupta A, Yewdall AW, Dale BM, Devi LA, et al. (2012) Cannabinoid Receptor 2-Mediated Attenuation of CXCR4-Tropic HIV Infection in Primary CD4+ T Cells. PLoS ONE 7(3): e33961. doi:10.1371/journal.pone.0033961

  14. Cota D et al. Endogenous Cannabinoid System as a Modulator of Food Intake. International Journal of Obesity (2003) 27, 289–301. www.nature.com/ijo

  15. Crippa, Effects of Cannabidiol on Regional Cerebral Blood Flow, Neuropsychopharmacology (2004) 29, 417–426

  16. Crippa et al. Neural basis of anxiolytic effects of cannabidiol in generalized social anxiety disorder: a preliminary report. J Psychopharmacol, 2010 doi:10.1177/0269881110379283

  17. Das, Cannabidiol enhances consolidation of explicit fear extinction in humans, Psychopharmacology (2013) 226:781–792, DOI 10.1007/s00213-012-2955-y

  18. Devinsky O et al. Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia, 55(6):791–802, 2014

  19. Elikottil J, Gupta P, Gupta K. The Analgesic Potential of Cannabinoids. Journal of Opioid Management. 5(6) : 341-357 (July 2013)

  20. El-Remessy etal. Neuroprotective Effect of D9-Tetrahydrocannabinol and Cannabidiol in N-Methyl-D-Aspartate-Induced Retinal Neurotoxicity, American Journal of Pathology, Vol. 163, No. 5, November 2003

  21. Fichna J, Wood JT, Papanastasiou M, Vadivel SK, Oprocha P, et al. (2013) Endocannabinoid and Cannabinoid-Like Fatty Acid Amide Levels Correlate with Pain-Related Symptoms in Patients with IBS-D and IBS-C: A Pilot Study. PLoS ONE 8(12): e85073. doi:10.1371/journal.pone.0085073

  22. Fine PG, Rosenfeld MJ. The Endocannabinoid System, Cannabinoids, and Pain. Rambam Maimonides Medical Journal. 4(4) 1-15 (Oct 2013).

  23. Freeman RM et al. The effect of cannabis on urge incontinence in patients with multiple sclerosis. Int Urogynecol J, 2006, DOI 10.1007/s00192-006-0086-x

  24. Fride I, Bregman T, et al. Endocannabinoids and Food Intake: Newborn Suckling and Appetite Regulation in Adulthood. Exp Biol Med 230:225–234, 2005

  25. Gaston, Interactions between cannabidiol and commonly used antiepileptic drugs, Epilepsia, **(*):1–7, 2017, doi: 10.1111/epi.13852

  26. Gloss D, Vickrey B. Cannabinoids for Epilepsy. the Cochrane Library, 2014 Mar 5;(3):CD009270. doi: 10.1002/14651858.CD009270.pub3.

  27. Hampson et al, Cannabidiol and D9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. USA Vol. 95, pp. 8268–8273, July 1998

  28. Hospodor A. Adjuvant Cannabinoid Therapy for Pancreatic Cancer. Presentation from Pancreatic Cancer: Innovations in Research and Treatment Conference, New Orleans, LA. May 2014.

  29. https://www.projectcbd.org/about/book-excerpt/cannabinoids-and-oxidation

  30. Jovanovic T and Norrholm SD. Neural mechanisms of impaired fear inhibition in posttraumatic stress disorder, Front Behav Neurosci. 2011; 5: 44. doi:  10.3389/fnbeh.2011.00044

  31. Krumm BA. Cannabis for Posttraumatic Stress Disorder: A Neurobiological Approach to Treatment.  The Nurse Practitioner. Vol. 41, No. 1 2016.

  32. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342(5):314-9

  33. Maor, Cannabidiol Inhibits Growth and Induces Programmed Cell Death in Kaposi Sarcoma– Associated Herpesvirus Infected Endothelium, Genes Cancer. 2012 Jul;3(7-8):512-20. doi: 10.1177/1947601912466556

  34. Marsicano, The endogenous cannabinoid system controls extinction of aversive memories, NATURE | VOL 418 | 1 AUGUST 2002

  35. Mechoulam & Fride, A Hunger for Cannabinoids, NATURE|VOL 410 | 12 APRIL 2001

  36. Mechoulam R, Panikashvili D, Shohami E. Cannabinoids and brain injury: therapeutic implications. TRENDS in Molecular Medicine Vol.8 No.2 February 2002

  37. Naftali T, et al. Cannabis Induces a Clinical Response in Patients with Crohn’s Disease: A Prospective Placebo-Controlled Study. Clinical Gastroenterology and Hepatology 2013; 11: 1276-1280.

  38. Nagarkatti P et al. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem. 2009 October; 1(7): 1333–1349. doi:10.4155/fmc.09.93.

  39. Nallathambi, et al.; Anti-Inflammatory Activity in Colon Models is Derived from Delta9-Tetrahydrocannabinolic Acid That Interacts with Additional Compounds in Cannabis Extracts. Cannabis and Cannabinoid Research 2017, 2.1 http://online.liebertpub.com/doi/10.1089/can.2017.0027

  40. Neumeister A, et al. Elevated Brain Cannabinoid CB1 Receptor Availability in Posttraumatic Stress Disorder: A Positron Emission Tomography Study. Mol Psychiatry. 2013 September; 18(9): 1034–1040. doi:10.1038/mp.2013.61.

  41. Pagano E, Borrelli F etal, (2016) An Orally Active Cannabis Extract with High Content in Cannabidiol attenuates Chemically-induced Intestinal Inflammation and Hypermotility in the Mouse. Pharmacol. 7:341. doi: 10.3389/fphar.2016.00341

  42. Parker LA, Rock EM, Limebeer CL.  Regulation of nausea and vomiting by cannabinoids, British Journal of Pharmacology (2011) 163 1411–1422, DOI:10.1111/j.1476-5381.2010.01176.x

  43. Passie T, et al. Mitigation of Post-Traumatic Stress Symptoms by Cannabis Resin: A Review of the Clinical and Neurobiological Evidence. Drug Testing and Analysis. 3 May 2012. DOI 10.1002/dta.137

  44. Pertwee, Cannabinoids and the gastrointestinal tract, Gut 2001;48:859–867

  45. Prentiss D, et al. Patterns of Marijuana Use Among Patients with HIV/AIDS Followed in a Public Health Care Setting. J Acquir Immune Defic Syndr. Volume 35, Number 1, January 1 2004.

  46. Pryce G, Ahmed Z, Hankey DJR, et al. Cannabinoids Inhibit Neurodegeneration in Models of Multiple Sclerosis. Brain (2003), 126, 2191±2202

  47. Raman C et al. 2004. Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotrophic Lateral Sclerosis & Other Motor Neuron Disorders 5: 33‐39.

  48. Recommendations Regarding the Use of Cannabis in Multiple Sclerosis. National Multiple Sclerosis Society. www.nationalmssociety.org/PRC

  49. Rosenberg EC, Tsien RW, Whalley BJ, Devinsky O. Cannabinoids and Epilepsy. Neurotherapeutics, 2015, doi:10.1007/s13311-015-0375-5

  50. Rossi S, Bozzali M, et al. Association Between a Genetic Variant Type-1 Cannabinoid Receptor and Inflammatory Neurodegeneration in Multiple Sclerosis. Plos One. December 2013, Volume 8, Issue 12, e82848.

  51. Russo E. Clinical Endocannabinoid Deficiency (CECD): Can This Concept Explain Therapeutic Benefits of Cannabis in Migraine, Fibromyalgia, Irritable Bowel Syndrome and Other Treatment-Resistant Conditions? Neuroendocrinology Letters. Nos.1/2, Feb-Apr Vol.25, 2004

  52. Russo E, Guy GW, Robson PJ. Cannabis, Pain, and Sleep: Lessons from Therapeutic Clinical Trials of Sativex, a Cannabis-Based Medicine. CHEMISTRY & BIODIVERSITY – Vol. 4 (2007)

  53. Russo E. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology (2011) 163 1344–1364

  54. Russo, Beyond Cannabis: Plants and the Endocannabinoid System, Trends in Pharmacological Sciences, July 2016, Vol. 37, No. 7 http://dx.doi.org/10.1016/j.tips.2016.04.005

  55. Russo E and Hohmann AG. Role of Cannabinoids in Pain Management, T.R. Deer et al. (eds.), Comprehensive Treatment of Chronic Pain by Medical, Interventional, and Integrative Approaches, 181, DOI 10.1007/978-1-4614-1560-2_18.

  56. Serpell etal. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment, Eur J Pain. 2014 Aug;18(7):999-1012. doi: 10.1002/j.1532-2149.2013.00445.x

  57. Sharkey, Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system, Eur J Pharmacol. 2014 January 5; 722: doi:10.1016/j.ejphar.2013.09.068.

  58. Slawson et al, High-intensity cannabis use and adherence to antiretroviral therapy among people who use illicit drugs in a Canadian setting, AIDS Behav. 2015 January; 19(1): 120–127. doi:10.1007/s10461-014-0847-3

  59. Sulak D, Saneto R, Goldstein B. The current status of artisanal cannabis for the treatment of epilepsy in the United States. Epilepsy Behav (2017),

  60. Tambaro S, Bortolato M. Cannabinoid-related Agents in the Treatment of Anxiety Disorders: Current Knowledge and Future Perspectives. Recent Patents on CNS Drug Discovery, 2012, 7, 25-40

  61. Tanasescum etal, Cannabinoids and the Immune System: An Overview, Immunobiology 215(2010)588–597

  62. Tibiriça, The multiple functions of the endocannabinoid system: a focus on the regulation of food intake. Diabetology & Metabolic Syndrome 2010 2:5. doi:10.1186/1758-5996-2-5

  63. Tomida I, et al. Cannabinoids and Glaucoma. Br J Ophthalmol 2004; 88:708-713 doi:10.1136/bjo.2003.032250

  64. Trezza V and Campolongo P. The Endocannabinoid System as a Possible Target to Treat Both the Cognitive and Emotional Features of Post-Traumatic Stress Disorder (PTSD). Frontiers in Behavioral Neuroscience. 09 August 2013 doi: 10.3389/fnbeh.2013.00100

  1. Velasco, G. et al. The use of cannabinoids as anticancer agents. Prog Neuro-Psychopharmacol Biol Psychiatry (2015), http://dx.doi.org/10.1016/j.pnpbp.2015.05.010

  2. Velasco G, Sanchez C, and Guzman M. Anticancer Mechanisms of Cannabinoids. Current Oncology. Mar; 23(S2): S23-S32 (2016)

  3. Wallace MJ et al. The Endogenous Cannabinoid System Regulates Seizure Frequency and Duration in a Model of Temporal Lobe Epilepsy. The Journal of Pharmacology and Experimental Therapeutics Vol. 307, No. 1, 2003

  1. Zanelati TV, Biojone C, et al. Antidepressant-Like Effects of Cannabidiol in Mice: Possible Involvement of 5-HT1A Receptors. British Journal of Pharmacology (2010), 159, 122–128

  2. Zettl UK et al. Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity. Therapeutic Advances in Neurological Disorders, 2016, Vol. 9(1) 9–30 DOI: 10.1177/ 1756285615612659

  70. Zurier, etal, Cannabinoids, inflammation, and fibrosis, FASEB J. 30, 3682–3689 (2016).   doi: 10.1096/fj.201600646R>


There was an error please try again.
LOGIN